Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor That Affords Robust CNS A(beta) Reduction
Stamford, A.W., Scott, J.D., Li, S.W., Babu, S., Tadesse, D., Hunter, R., Wu, Y., Misiaszek, J., Cumming, J.N., Gilbert, E.J., Huang, C., McKittrick, B.A., Hong, L., Guo, T., Zhu, Z., Strickland, C., Orth, P., Voigt, J.H., Kennedy, M.E., Chen, X., Kuvelkar, R., Hodgson, R., Hyde, L.A., Cox, K., Favreau, L., Parker, E.M., Greenlee, W.J.(2012) ACS Med Chem Lett 3: 897-902
- PubMed: 23412139 
- DOI: 10.1021/ml3001165
- Primary Citation of Related Structures:  
4FRS - PubMed Abstract: 
Inhibition of BACE1 to prevent brain Aβ peptide formation is a potential disease-modifying approach to the treatment of Alzheimer's disease. Despite over a decade of drug discovery efforts, the identification of brain-penetrant BACE1 inhibitors that subs ...